SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 430.51 |
| Enterprise Value ($M) | 393.58 |
| Book Value ($M) | 123.51 |
| Book Value / Share | 1.60 |
| Price / Book | 3.49 |
| NCAV ($M) | 121.46 |
| NCAV / Share | 1.58 |
| Price / NCAV | 3.54 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.76 |
| Return on Assets (ROA) | -0.45 |
| Return on Equity (ROE) | -0.49 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.11 |
| Current Ratio | 13.11 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 137.25 |
| Assets | 139.31 |
| Liabilities | 15.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.02 |
| Operating Income | -103.17 |
| Net Income | -95.06 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -79.85 |
| Cash from Investing | -28.39 |
| Cash from Financing | 10.04 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ameriprise Financial Inc | 7.40 | 35.57 | |
| 13G/A | BlackRock, Inc. | 8.70 | 52.28 | |
| 13G/A | State Street Corp | 4.80 | -12.67 | |
| 13G/A | Millennium Management Llc | 0.20 | -95.05 | |
| 13G/A | Nuveen Asset Management, LLC | 2.88 | ||
| 13G/A | Teachers Advisors, Llc | 2.88 | ||
| 13G/A | Tiaa Cref Investment Management Llc | 2.88 | -47.11 | |
| 13G/A | Avidity Partners Management LP | 0.00 | -100.00 | |
| 13G/A | Tang Capital Partners Lp | 5.10 | 1.83 | |
| 13G/A | Vanguard Group Inc | 6.65 | 41.05 | |
| 13G/A | Janus Henderson Group Plc | 0.00 | -99.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| 2024 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 410,202 | 2,202,350 | 18.63 | |
| 568,047 | 2,680,083 | 21.20 | |
| 468,700 | 2,914,646 | 16.08 | |
| 553,459 | 2,583,720 | 21.42 | |
| 614,249 | 2,427,564 | 25.30 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACRV – Acrivon Therapeutics, Inc. | ADMA – ADMA Biologics, Inc. |
| AFMD – Affimed N.V. | ANIP – ANI Pharmaceuticals, Inc. |
| APGE – Apogee Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io